MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after ...

Core Viewpoint - Mainz Biomed N.V. is shifting its focus to the pancreatic cancer detection business in the U.S. while engaging in strategic asset sales to enhance liquidity and explore growth opportunities [1][3]. Group 1: Strategic Transactions - The company entered into a securities purchase agreement for a $6.0 million private placement with investor David Lazar, structured in two tranches of $3.0 million each [2]. - The first tranche was completed on February 13, 2026, with the second tranche expected to close before April 15, 2026, pending stockholder approvals [2]. - Proceeds from the private placement will be used to fund ongoing operations, address liabilities, and maintain operational flexibility [2][3]. Group 2: Business Focus and Operations - Mainz Biomed is concentrating on developing its pancreatic cancer screening program in the U.S. while evaluating opportunities to sell its colorectal cancer screening assets [3]. - The company is in discussions with multiple parties interested in its colorectal cancer assets, which will help reduce operating expenses and extend its financial runway [3]. Group 3: Leadership Changes - David Lazar has been appointed as Chairman of the Board of Directors following the financing agreement [2][3]. Group 4: Product Portfolio - Mainz Biomed's flagship product is ColoAlert, a non-invasive early-detection test for colorectal cancer, marketed in Europe [5]. - The company is also developing PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of biomarkers in blood and stool samples [5].

Core Insights - GRAIL, Inc. will announce its financial results for the fourth quarter and full year 2025 on February 19, 2026, after market close [1] - A webcast and conference call will be held at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and business progress [1] Company Overview - GRAIL is a healthcare company focused on early cancer detection, aiming to alleviate the global burden of cancer [1] - The company utilizes next-generation sequencing, population-scale clinical studies, and advanced machine learning to identify multiple cancer types at earlier stages [1] - GRAIL's platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [1] - The company is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [1]

Core Insights - In 2025, small-cap stocks underperformed compared to large-cap stocks, with the Russell 2000 Index delivering a total return of approximately 13%, while the S&P 500 Index achieved around 18% [2] - Despite the overall underperformance, three small-cap stocks achieved exceptional returns of 300% or more, transitioning into mid-cap status [3] Company Performance - GRAIL, a healthcare company focused on early cancer detection, saw its stock price increase by approximately 380% in 2025, raising its market capitalization from below $1 billion to around $3.3 billion [3] - GRAIL's main product, the Galleri Multi-Cancer Early Detection test, is designed to detect over 50 types of cancer, significantly improving early detection rates [4] - The company plans to apply for Premarket Approval (PMA) from the U.S. FDA in Q1 2026, which could lead to commercial insurers covering the test, unlocking a new sales channel [5] Market Outlook - Analysts have a consensus price target of $97.50 for GRAIL, indicating an optimistic outlook with an implied upside of around 14% [6]

Core Insights - GRAIL, Inc. is focused on early cancer detection, aiming to identify cancer when it is still curable [2][4] - The company will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 [1] Company Overview - GRAIL utilizes next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect multiple types of cancer at earlier stages [2] - The company's platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [2] - GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [2]

Core Insights - GRAIL, Inc. is focused on early cancer detection, aiming to identify cancer when it is still curable [2][4] - The company will present at the 7th Annual Wolfe Research Healthcare Conference on November 18, 2025 [1] Company Overview - GRAIL utilizes next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect multiple cancer types at earlier stages [2] - The company’s platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [2] - GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [2] Financial Updates - GRAIL announced a $325.0 million private placement financing [5]

Core Insights - GRAIL, Inc. is focused on early cancer detection, aiming to identify cancer when it is still curable [2][4] - The company will present at the Bernstein Insights: Healthcare Leaders and Disruptors forum on September 24, 2025 [1] Company Overview - GRAIL utilizes next-generation sequencing, population-scale clinical studies, and advanced machine learning to detect multiple cancer types at earlier stages [2] - The company's platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [2] - GRAIL is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [2]

Company Overview - GRAIL, Inc. is a healthcare company focused on early cancer detection when it can be cured [3] - The company utilizes next-generation sequencing, population-scale clinical studies, and advanced machine learning to identify multiple cancer types at earlier stages [3] - GRAIL's platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [3] Upcoming Event - GRAIL management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 13 at 8:30 a.m. ET [1] - Live and replay webcasts of the presentation will be available on GRAIL's investor relations website for at least 30 days [2]

Core Insights - GRAIL, Inc. is set to release its financial results for the second quarter of 2025 on August 12, 2025, after market close [1] - Following the financial results announcement, GRAIL management will conduct a webcast and conference call to discuss the results and business progress [1] Company Overview - GRAIL is a healthcare company focused on early cancer detection, aiming to alleviate the global burden of cancer through advanced technologies [4] - The company utilizes next-generation sequencing, population-scale clinical studies, and machine learning to identify multiple cancer types at earlier stages [4] - GRAIL's platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [4] - The company is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [4]

Core Viewpoint - GRAIL, Inc. is focused on early cancer detection to improve treatment outcomes and will present at the Jefferies Global Healthcare Conference 2025 [1] Company Overview - GRAIL is a healthcare company dedicated to detecting cancer early when it is most treatable [3] - The company utilizes next-generation sequencing, large-scale clinical studies, and advanced machine learning to identify multiple cancer types at earlier stages [3] - GRAIL's platform supports various aspects of cancer care, including multi-cancer early detection, risk stratification, and treatment monitoring [3] - The company is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [3]